Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026)

Longeveron's (LGVN) quarterly Net Income towards Common Stockholders came in at -$5.5 million in Q1 2026, up 14.64% year-on-year from -$4.8 million in Q1 2025, and down 1.86% quarter-over-quarter from -$5.4 million in Q4 2025.

Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Longeveron's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 14.64% year-over-year to -$5.5 million in Q1 2026; TTM through Mar 2026 was -$23.2 million, a 14.12% increase from a year earlier, with the FY2025 full-year figure at -$22.7 million, up 7.79% from the prior year.
  • Net Income towards Common Stockholders retreated to -$5.5 million in Q1 2026 per LGVN's latest filing, from -$5.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$4.1 million in Q4 2024 and bottomed at -$42.7 million in Q1 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$5.4 million (2025), against an average of -$7.9 million.
  • Across the five-year window, Net Income towards Common Stockholders plunged 942.87% in 2023 and soared 89.9% in 2024, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$4.5 million in 2022, then sank by 35.25% to -$6.0 million in 2023, then surged by 32.3% to -$4.1 million in 2024, then slumped by 33.4% to -$5.4 million in 2025, then decreased by 1.86% to -$5.5 million in 2026.
  • Per Business Quant, the three latest LGVN Net Income towards Common Stockholders figures stand at -$5.5 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Longeveron 14.87 Bn 14.86 Bn 264,000.00 -5.55 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.55 Mn
Dec 31, 2025 -5.44 Mn
Sep 30, 2025 -7.22 Mn
Jun 30, 2025 -5.03 Mn
Mar 31, 2025 -6.50 Mn
Dec 31, 2024 -4.08 Mn
Sep 30, 2024 -4.57 Mn
Jun 30, 2024 -11.91 Mn
Mar 31, 2024 -4.31 Mn
Dec 31, 2023 -6.03 Mn
Sep 30, 2023 -5.90 Mn
Jun 30, 2023 -5.63 Mn
Mar 31, 2023 -42.72 Mn
Dec 31, 2022 -4.46 Mn
Sep 30, 2022 -5.24 Mn
Jun 30, 2022 -4.92 Mn
Mar 31, 2022 -4.10 Mn
Dec 31, 2021 44.90 Mn
Sep 30, 2021 -22.91 Mn
Jun 30, 2021 -20.06 Mn